AU2021263474A1 - Processes for the preparation of a kinase inhibitor - Google Patents
Processes for the preparation of a kinase inhibitor Download PDFInfo
- Publication number
- AU2021263474A1 AU2021263474A1 AU2021263474A AU2021263474A AU2021263474A1 AU 2021263474 A1 AU2021263474 A1 AU 2021263474A1 AU 2021263474 A AU2021263474 A AU 2021263474A AU 2021263474 A AU2021263474 A AU 2021263474A AU 2021263474 A1 AU2021263474 A1 AU 2021263474A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- solvent
- formula
- reaction mixture
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017739P | 2020-04-30 | 2020-04-30 | |
| US63/017,739 | 2020-04-30 | ||
| PCT/US2021/030035 WO2021222673A1 (en) | 2020-04-30 | 2021-04-30 | Processes for the preparation of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021263474A1 true AU2021263474A1 (en) | 2022-11-17 |
Family
ID=76076455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021263474A Pending AU2021263474A1 (en) | 2020-04-30 | 2021-04-30 | Processes for the preparation of a kinase inhibitor |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12497367B2 (https=) |
| EP (1) | EP4143169B1 (https=) |
| JP (2) | JP7728795B2 (https=) |
| KR (1) | KR20230005190A (https=) |
| CN (2) | CN115461328B (https=) |
| AU (1) | AU2021263474A1 (https=) |
| BR (1) | BR112022021712A2 (https=) |
| CA (1) | CA3176042A1 (https=) |
| CL (1) | CL2022003008A1 (https=) |
| CO (1) | CO2022015205A2 (https=) |
| CR (1) | CR20220551A (https=) |
| GE (1) | GEP20267875B (https=) |
| IL (2) | IL297684B1 (https=) |
| MX (1) | MX2022013528A (https=) |
| PE (1) | PE20230110A1 (https=) |
| PH (1) | PH12022552821A1 (https=) |
| TW (1) | TWI887405B (https=) |
| WO (1) | WO2021222673A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1154105A (zh) * | 1994-06-08 | 1997-07-09 | H·隆德贝克有限公司 | 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物 |
| ZA954689B (en) | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines |
| CN101466672B (zh) * | 2006-06-12 | 2012-05-16 | 诺瓦提斯公司 | N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐 |
| NZ572547A (en) | 2006-06-12 | 2011-06-30 | Novartis Ag | SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-yl)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE |
| JP5486606B2 (ja) * | 2008-11-13 | 2014-05-07 | エクセリクシス， インク． | キノリン誘導体の調製方法 |
| NZ779754A (en) * | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| EA030435B1 (ru) | 2010-07-16 | 2018-08-31 | Экселиксис, Инк. | ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ |
| CN104395284A (zh) | 2011-10-20 | 2015-03-04 | 埃克塞里艾克西斯公司 | 制备喹啉衍生物的方法 |
| EP3174854B1 (en) | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| CR20250117A (es) | 2018-01-26 | 2025-05-09 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355) |
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| CA3088198A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| KR102828472B1 (ko) * | 2018-12-13 | 2025-07-03 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| CN109761899B (zh) | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2021
- 2021-04-30 CN CN202180031136.7A patent/CN115461328B/zh active Active
- 2021-04-30 MX MX2022013528A patent/MX2022013528A/es unknown
- 2021-04-30 KR KR1020227037607A patent/KR20230005190A/ko active Pending
- 2021-04-30 EP EP21727657.5A patent/EP4143169B1/en active Active
- 2021-04-30 CN CN202511511945.4A patent/CN121591655A/zh active Pending
- 2021-04-30 CA CA3176042A patent/CA3176042A1/en active Pending
- 2021-04-30 JP JP2022566135A patent/JP7728795B2/ja active Active
- 2021-04-30 AU AU2021263474A patent/AU2021263474A1/en active Pending
- 2021-04-30 US US17/922,208 patent/US12497367B2/en active Active
- 2021-04-30 PH PH1/2022/552821A patent/PH12022552821A1/en unknown
- 2021-04-30 CR CR20220551A patent/CR20220551A/es unknown
- 2021-04-30 PE PE2022002513A patent/PE20230110A1/es unknown
- 2021-04-30 WO PCT/US2021/030035 patent/WO2021222673A1/en not_active Ceased
- 2021-04-30 TW TW110115786A patent/TWI887405B/zh active
- 2021-04-30 GE GEAP202516101A patent/GEP20267875B/en unknown
- 2021-04-30 BR BR112022021712A patent/BR112022021712A2/pt unknown
-
2022
- 2022-10-26 IL IL297684A patent/IL297684B1/en unknown
- 2022-10-26 CO CONC2022/0015205A patent/CO2022015205A2/es unknown
- 2022-10-28 CL CL2022003008A patent/CL2022003008A1/es unknown
-
2025
- 2025-06-20 JP JP2025104881A patent/JP2025128388A/ja active Pending
- 2025-10-21 IL IL324105A patent/IL324105A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115461328A (zh) | 2022-12-09 |
| GEP20267875B (en) | 2026-03-25 |
| EP4143169B1 (en) | 2026-04-15 |
| JP2025128388A (ja) | 2025-09-02 |
| CL2022003008A1 (es) | 2023-06-23 |
| TW202208335A (zh) | 2022-03-01 |
| MX2022013528A (es) | 2022-11-16 |
| PH12022552821A1 (en) | 2024-02-12 |
| CR20220551A (es) | 2022-12-07 |
| CN121591655A (zh) | 2026-03-03 |
| US20230192619A1 (en) | 2023-06-22 |
| IL297684B1 (en) | 2026-03-01 |
| EP4143169A1 (en) | 2023-03-08 |
| CN115461328B (zh) | 2025-11-07 |
| CO2022015205A2 (es) | 2022-10-31 |
| PE20230110A1 (es) | 2023-01-25 |
| IL297684A (en) | 2022-12-01 |
| BR112022021712A2 (pt) | 2022-12-06 |
| IL324105A (en) | 2025-12-01 |
| US12497367B2 (en) | 2025-12-16 |
| JP2023524692A (ja) | 2023-06-13 |
| WO2021222673A1 (en) | 2021-11-04 |
| JP7728795B2 (ja) | 2025-08-25 |
| TWI887405B (zh) | 2025-06-21 |
| CA3176042A1 (en) | 2021-11-04 |
| KR20230005190A (ko) | 2023-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2742234C1 (ru) | Кумариноподобное циклическое соединение в качестве ингибитора мек и его применение | |
| ES2905973T3 (es) | Proceso para la preparación de diclorhidrato de 5-cloro-N2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-N4-[2-(propano-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
| ES2772498T3 (es) | Preparación de un inhibidor mek y formulación que comprende el mismo | |
| IL324105A (en) | Processes for the preparation of a kinase inhibitor | |
| AU2018236290A1 (en) | MK2 inhibitors, synthesis thereof, and intermediates thereto | |
| WO2022165148A1 (en) | Mk2 inhibitors, the synthesis thereof, and intermediates thereto | |
| AU2016246068B2 (en) | Xanthine-substituted alkynyl carbamates/reverse carbamates as A2b antagonists | |
| KR20190035680A (ko) | 벨리노스테트의 다형태 및 이의 제조 방법 | |
| KR20070036025A (ko) | 치환된 트리아졸 화합물의 제조방법 | |
| BR112018016708B1 (pt) | Compostos de 7h-pirrolo[2,3-d]pirimidina e processo para preparar os ditos compostos | |
| JP7068402B2 (ja) | チアゾール誘導体の製造方法 | |
| CN118359632A (zh) | 喜树碱衍生物、其制备方法及其用途 | |
| EA052237B1 (ru) | Способы получения ингибитора киназы | |
| TWI908573B (zh) | 芳香醯肼類衍生物及其醫藥用途 | |
| KR20150001936A (ko) | 게피티닙의 신규한 결정형 및 이의 제조방법 | |
| AU2018351539A1 (en) | Preparation method for tyrosine kinase inhibitor and intermediate thereof | |
| JP2021531302A (ja) | アゼチジン誘導体のボレート | |
| CN111943853B (zh) | 一种培唑帕尼杂质的制备方法 | |
| EP4650354A1 (en) | Indolone derivative having irak4 inhibitory activity, and preparation method therefor and use thereof | |
| CA3214107A1 (en) | New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds | |
| WO2025231105A1 (en) | Processes of making csf-1r inhibitors and methods of use thereof |